In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Caredx Inc’s stock clocked out at $22.84, up 1.29% from its previous closing price of $22.55. In other words, the price has increased by $1.29 from its previous closing price. On the day, 0.77 million shares were traded. CDNA stock price reached its highest trading level at $23.2 during the session, while it also had its lowest trading level at $22.425.
Ratios:
To gain a deeper understanding of CDNA’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.09 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 1004.09. For the most recent quarter (mrq), Quick Ratio is recorded 3.87 and its Current Ratio is at 4.10. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on January 15, 2025, Upgraded its rating to Equal Weight and sets its target price to $24 from $28 previously.
On August 28, 2024, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $28.
BTIG Research Upgraded its Neutral to Buy on August 19, 2024, while the target price for the stock was maintained at $40.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 04 ’24 when Novack Jeffrey Adam sold 1,917 shares for $26.00 per share. The transaction valued at 49,842 led to the insider holds 110,237 shares of the business.
Jeffrey Adam Novack bought 1,917 shares of CDNA for $47,848 on Dec 04 ’24. On Nov 26 ’24, another insider, Maag Peter, who serves as the Director of the company, sold 5,000 shares for $25.00 each. As a result, the insider received 125,000 and left with 330,024 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDNA now has a Market Capitalization of 1224998272 and an Enterprise Value of 1014109632. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.92 while its Price-to-Book (P/B) ratio in mrq is 4.44. Its current Enterprise Value per Revenue stands at 3.242 whereas that against EBITDA is -22.915.
Stock Price History:
The Beta on a monthly basis for CDNA is 1.87, which has changed by 1.6343458 over the last 52 weeks, in comparison to a change of 0.25219524 over the same period for the S&P500. Over the past 52 weeks, CDNA has reached a high of $34.84, while it has fallen to a 52-week low of $7.42. The 50-Day Moving Average of the stock is -0.14%, while the 200-Day Moving Average is calculated to be 8.25%.
Shares Statistics:
It appears that CDNA traded 789.82K shares on average per day over the past three months and 969830 shares per day over the past ten days. A total of 53.11M shares are outstanding, with a floating share count of 50.22M. Insiders hold about 6.36% of the company’s shares, while institutions hold 97.05% stake in the company. Shares short for CDNA as of 1736899200 were 4388685 with a Short Ratio of 5.56, compared to 1734048000 on 3118083. Therefore, it implies a Short% of Shares Outstanding of 4388685 and a Short% of Float of 10.79.
